Additional Studies. During the Term and continuing [***], Corvus agrees to negotiate exclusively with Genentech for a period of [***] prior to entering into any clinical study or clinical development agreement with a Third Party involving the combination of Corvus Molecule and any PD-L1 Antagonist or PD-1 Antagonist. During such [***], the Parties shall discuss in good faith the terms and conditions for collaborating with each other to conduct further clinical studies of the Combination, including terms [***].
Appears in 4 contracts
Samples: Phase I/Ib Combination Study Agreement (Corvus Pharmaceuticals, Inc.), Phase I/Ib Combination Study Agreement (Corvus Pharmaceuticals, Inc.), Phase I/Ib Combination Study Agreement (Corvus Pharmaceuticals, Inc.)
